Description
Abiraterone is a CYP17 inhibitor, which is mainly clinically used to treat prostate cancer patients. Its product ZYTIGA was developed by Janssen-Cilag International NV(a subsidiary of Johnson & Johnson). In 2015, Abiraterone entered the Chinese market. As of 2020, in addition to Janssen-Cilag International NV, the main manufacturers of Abiraterone in China are Chengdu Suncadia Medicine Co., Ltd., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangxi Shanxiang Pharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.

According to CRI’s market research, from 2016 to 2019, Abiraterone’s sales in the Chinese market have shown an upward trend. In 2017, the price of Abiraterone dropped and it was included in China’s national medical insurance. Therefore, the sales of Abiraterone in the Chinese market increased the most significantly from 2017 to 2019. The annual sales revenue in 2019 is CNY566.84 million, which increased over 30 times compared to that in 2016. The outbreak of the COVID-19 epidemic in 2020 has impacted the overall diagnosis and treatment business of Chinese hospitals, so the sales value of Abiraterone in the Chinese market declined slightly in 2020. The CAGR of Abiraterone sales value in the Chinese market from 2016 to 2020 is 140.7%.

CRI analyzes that from 2021 to 2025, Abiraterone’s sales in China will continue to grow as the improvement of COVID-19 epidemic. According to data from China National Cancer Registration Institute, prostate cancer has become the most common tumor in male urinary malignancies since 2008. As the incidence and mortality of this cancer continue to rise, and its sales will also increase.

Topics Covered:

  • The impact of COVID-19 on China’s Abiraterone market
  • Sales value of China’s Abiraterone 2016-2020
  • Competitive landscape of China’s Abiraterone market
  • Prices of Abiraterone in China
  • Prices of Abiraterone in China by regions and manufacturers
  • Analysis of factors affecting the development of China’s Abiraterone market
  • Prospect of China’s Abiraterone market from 2021 to 2025